carbostyril has been researched along with Acute Relapsing Multiple Sclerosis in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (16.67) | 29.6817 |
| 2010's | 22 (73.33) | 24.3611 |
| 2020's | 3 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abbastabar, H; Bitarafan, S; Harirchian, MH; Mohammadpour, Z; Noureini, SK; Rouhi, F | 1 |
| Engel, S; Furlan, R; Jolivel, V; Kraus, SH; Kurschus, FC; Luessi, F; Rosenfeld, K; Tumani, H; Waisman, A; Zayoud, M | 1 |
| Boyko, A; Comi, G; Dadon, Y; Filippi, M; Halevy, N; Knappertz, V; Lublin, FD; Montalban, X; Rocca, MA; Rubinchick, S; Sasson, N; Steinerman, JR; Vermersch, P; Volkinshtein, R; Vollmer, TL; Ziemssen, T | 1 |
| Bar-Ilan, O; Hayardeny, L; Mimrod, D; Paul, F; Richter, N; Samara, E; Sehr, T; Sorani, E; Spiegelstein, O; Thomas, K; Tumani, H; Ziemssen, T | 1 |
| Furlan, R; Hubo, M; Jolivel, V; Jonuleit, H; Klebow, S; Kraus, SH; Luessi, F; Masri, J; Paterka, M; Poisa-Beiro, L; Siffrin, V; Tumani, H; Waisman, A; Yogev, N; Zipp, F | 1 |
| Boĭko, AN; Gusev, EI | 1 |
| Chu, L; Dong, S; Feng, Z; Gao, X; Han, K; He, D; Wu, S | 1 |
| Brück, W; Vollmer, T | 1 |
| Carreón-Guarnizo, E; Hernández-Clares, R; Meca-Lallana, JE | 1 |
| Achiron, A; Gurevich, M; Hayardeny, L; Zilkha-Falb, R | 1 |
| Constantinescu, CS; Constantinescu, SE | 1 |
| Hainke, U; Thomas, K; Ziemssen, T | 1 |
| Cutter, GR; Knappertz, V; Ladkani, D; Sasson, N | 1 |
| Alvarez, JI; Eckert, N; Flügel, A; Hayardeny, L; Kebir, H; Litke, T; Lodygin, D; Lühder, F; Odoardi, F; Prat, A; Sonneck, M; Sorani, E; Winchenbach, J | 1 |
| Keegan, BM; Weinshenker, BG | 1 |
| Abramsky, O; Arbizu, T; Boiko, A; Comi, G; Filippi, M; Gold, R; Havrdova, E; Komoly, S; Pulizzi, A; Rovaris, M; Selmaj, K; Sharrack, B | 1 |
| Weiner, HL | 1 |
| Preiningerova, J | 1 |
| Achiron, A; Feldman, A; Gritzman, T; Gurevich, M; Orbach, R; Tuller, T | 1 |
| Tselis, A | 1 |
| Abramsky, O; Arbizu, T; Boyko, A; Comi, G; Filippi, M; Gold, R; Havrdová, E; Komoly, S; Selmaj, K; Sharrack, B | 1 |
| Gold, R; Thöne, J | 1 |
| Bar-Or, A; Giacomini, PS | 1 |
| Csépány, T | 1 |
| Killestein, J; Polman, CH; Rudick, RA | 1 |
| Boyko, A; Comi, G; Filippi, M; Jeffery, D; Kappos, L; Montalban, X; Rocca, MA | 1 |
| Brück, W; Zamvil, SS | 1 |
| Pagola, I; Palma, JA | 1 |
| Methner, A; Zipp, F | 1 |
| Barkhof, F; Linde, A; Nederman, T; Nordle, O; Polman, C; Sandberg-Wollheim, M | 1 |
13 review(s) available for carbostyril and Acute Relapsing Multiple Sclerosis
| Article | Year |
|---|---|
The effects and side effects of laquinimod for the treatment of multiple sclerosis patients: a systematic review and meta-analysis of clinical trials.
Topics: Adult; Female; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Quinolones | 2020 |
[Laquinimod is an oral drug with a marked neuroprotective effect for pathogenetic treatment of multiple sclerosis(review)].
Topics: Administration, Oral; Humans; Multiple Sclerosis, Relapsing-Remitting; Neuroprotective Agents; Quinolones; Treatment Outcome | 2013 |
Laquinimod for multiple sclerosis.
Topics: Administration, Oral; Adult; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Quinolones; Randomized Controlled Trials as Topic; Secondary Prevention | 2013 |
[Oral treatments in multiple sclerosis].
Topics: Administration, Oral; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2014 |
Laquinimod (ABR-215062) for the treatment of relapsing multiple sclerosis.
Topics: Administration, Oral; Animals; Brain; Disease Models, Animal; Disease Progression; Humans; Immunologic Factors; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Quinolones | 2016 |
Laquinimod in the treatment of relapsing remitting multiple sclerosis.
Topics: Administration, Oral; Animals; Disease Models, Animal; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Humans; Immunologic Factors; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Neuritis, Autoimmune, Experimental; Quinolones | 2016 |
Oral laquinimod therapy in relapsing multiple sclerosis.
Topics: Administration, Oral; Animals; Humans; Immunologic Factors; Multiple Sclerosis, Relapsing-Remitting; Quinolones | 2009 |
Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis.
Topics: Animals; Clinical Trials as Topic; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Quinolones; Treatment Outcome | 2011 |
Laquinimod in multiple sclerosis.
Topics: Animals; Clinical Trials as Topic; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Quinolones | 2012 |
[Current treatment of multiple sclerosis].
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cladribine; Dimethyl Fumarate; Drug Administration Schedule; Fingolimod Hydrochloride; Fumarates; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peptides; Propylene Glycols; Quinolones; Sphingosine; Treatment Outcome | 2011 |
Oral treatment for multiple sclerosis.
Topics: Administration, Oral; Cladribine; Clinical Trials as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2011 |
Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis.
Topics: Administration, Oral; Animals; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Encephalomyelitis, Autoimmune, Experimental; Humans; Mice; Models, Animal; Multiple Sclerosis, Relapsing-Remitting; Quinolones | 2012 |
Multiple sclerosis in 2012: Novel therapeutic options and drug targets in MS.
Topics: Clinical Trials as Topic; Dimethyl Fumarate; Fumarates; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Potassium Channels, Inwardly Rectifying; Quinolones; Receptors, Tumor Necrosis Factor, Type I; T-Lymphocytes | 2013 |
7 trial(s) available for carbostyril and Acute Relapsing Multiple Sclerosis
| Article | Year |
|---|---|
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis.
Topics: Double-Blind Method; Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Quinolones; Recurrence | 2022 |
Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS.
Topics: Administration, Oral; Adolescent; Adult; Cohort Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Immunity, Innate; Immunologic Factors; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Quinolones; Young Adult | 2017 |
Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree.
Topics: Humans; Immunologic Factors; Multiple Sclerosis, Relapsing-Remitting; Propensity Score; Quinolones; Randomized Controlled Trials as Topic | 2016 |
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Topics: Adolescent; Adult; Double-Blind Method; Humans; Magnetic Resonance Imaging; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Quinolones; Treatment Outcome | 2008 |
Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study.
Topics: Administration, Oral; Brain; Disability Evaluation; Double-Blind Method; Humans; Immunologic Factors; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Quinolones | 2010 |
Placebo-controlled trial of oral laquinimod for multiple sclerosis.
Topics: Adult; Brain; Cough; Disease Progression; Double-Blind Method; Female; Humans; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Pain; Quinolones | 2012 |
Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
Topics: Administration, Oral; Adult; Central Nervous System; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Placebos; Quinolones; Treatment Outcome | 2005 |
10 other study(ies) available for carbostyril and Acute Relapsing Multiple Sclerosis
| Article | Year |
|---|---|
Laquinimod dampens IL-1β signaling and Th17-polarizing capacity of monocytes in patients with MS.
Topics: Adult; Cross-Sectional Studies; Female; Humans; Interleukin-1beta; Lymphocyte Activation; Male; Middle Aged; Monocytes; Multiple Sclerosis, Relapsing-Remitting; Quinolones; Signal Transduction; Th17 Cells | 2021 |
Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.
Topics: Animals; CD4-Positive T-Lymphocytes; Dendritic Cells; Encephalomyelitis, Autoimmune, Experimental; Female; Humans; Mice; Mice, Inbred C57BL; Multiple Sclerosis, Relapsing-Remitting; NF-kappa B; Quinolones | 2013 |
Multiple sclerosis: Oral laquinimod for MS--bringing the brain into focus.
Topics: Brain; Female; Humans; Male; Multiple Sclerosis, Relapsing-Remitting; Quinolones | 2013 |
The role of laquinimod in modulation of the immune response in relapsing-remitting multiple sclerosis: Lessons from gene expression signatures.
Topics: Adult; Cell Adhesion; Chemotaxis, Leukocyte; Cytokines; Down-Regulation; Female; Gene Expression Profiling; Gene Expression Regulation; Humans; Immunologic Factors; Inflammation; Male; Multiple Sclerosis, Relapsing-Remitting; NF-kappa B; Quinolones; RNA, Messenger; Signal Transduction; Transforming Growth Factor beta | 2015 |
Laquinimod enhances central nervous system barrier functions.
Topics: Adult; Animals; Blood-Brain Barrier; Capillary Permeability; Cells, Cultured; Encephalomyelitis, Autoimmune, Experimental; Endothelial Cells; Female; Humans; Lymphocytes; Male; Mice, Inbred C57BL; Mice, Transgenic; Multiple Sclerosis, Relapsing-Remitting; Neuroprotective Agents; Quinolones; Rats, Inbred Lew; T-Lymphocytes; Young Adult | 2017 |
Laquinimod, a new oral drug for multiple sclerosis.
Topics: Administration, Oral; Humans; Multiple Sclerosis, Relapsing-Remitting; Quinolones | 2008 |
Oral laquinimod for treatment of relapsing-remitting multiple sclerosis.
Topics: Administration, Oral; Humans; Multiple Sclerosis, Relapsing-Remitting; Quinolones | 2008 |
Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study.
Topics: Adult; Antigen Presentation; Antigens, CD; Cell Survival; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Gene Expression Regulation; Humans; Immunologic Factors; Killer Cells, Natural; Leukocytes, Mononuclear; Middle Aged; Models, Immunological; Multiple Sclerosis, Relapsing-Remitting; NF-kappaB-Inducing Kinase; Oligonucleotide Array Sequence Analysis; Protein Array Analysis; Protein Serine-Threonine Kinases; Quinolones | 2010 |
Laquinimod, a new oral autoimmune modulator for the treatment of relapsing-remitting multiple sclerosis.
Topics: Animals; Clinical Trials as Topic; Drug Design; Drug Evaluation, Preclinical; Humans; Immunosuppressive Agents; Molecular Structure; Multiple Sclerosis, Relapsing-Remitting; Quinolones; Treatment Outcome | 2010 |
Oral laquinimod for multiple sclerosis.
Topics: Brain; Female; Humans; Male; Multiple Sclerosis, Relapsing-Remitting; Quinolones | 2012 |